You will be redirected back to your article in seconds
Skip to main content

Novozymes Acquires Land for New R&D Facility

Bioinnovation firm Novozymes, the world’s largest maker of enzymes, finalized a deal Friday to build a new research and development facility on a massive 1.5-million-square-foot site near the Technical University of Denmark (DTU) in Lyngby, just north of Copenhagen.

“This is an investment in the future, where the new innovation campus will be a cornerstone for our global research. Novozymes is driven by innovation and this center will help strengthen our growth through developing ground-breaking technology,” said the company’s executive vice president for R&D, Per Falholt.

Roughly 14 percent of Novozymes’ revenue is reinvested into research annually, leading to the development of more than 100 new products over the past 15 years. The firm is a founding partner of LAUNCH Nordic, a strategic collaboration between Nike, NASA and the U.S. Agency for International Development (USAID), as well as a member of the Sustainable Apparel Coalition, two initiatives seeking more sustainable solutions in the apparel industry’s supply chain. It currently holds more than 7,000 granted or pending patents and in 2014, the Dow Jones Sustainability Index ranked Novozymes among the top 3 percent of companies in the chemical industry sector.

“Novozymes’ project is ambitious and fits perfectly into our goal of developing as a knowledge and university city,” said Sofia Osmani, mayor of Lyngby-Taarbaek. “The new innovation campus will strengthen education, research and business in the municipality. And Novozymes also shares our ambition to maintain and develop the area as a green recreational oasis.”

Headquartered in Bagsvaerd, Novozymes currently has two production facilities in Denmark and employs 2,700, a number that’s grown by around 600 since 2005, which sparked the decision to develop the new campus. “With the location in Lyngby, in close proximity to Denmark’s Technical University, our ambition is to create a global hub for biotech research,” Falholt added, noting that the facility will include a learning center with teaching laboratories, a small cinema and a café, and will function as a link to the research environment in Lyngby.

Construction will first start on a 322,000-square-foot facility that’s expected to meet the company’s space needs until 2023, while a later expansion will make it possible to house up to 2,500 employees. Units from Bagsvaerd will move to the Lyngby facility once it is established in 2018, pending the approval of the district plan.